Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0
|
作者：
Maw, May Tun Hla [1 ]
Malik, Laeeq [1 ]
机构：
[1] Canberra Hosp, Dept Med Oncol, Garran, ACT, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
206
引用
收藏
页码：127 / 127
页数：1
相关论文
共 50 条
  • [31] Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)
    Custodio-Cabello, Sara
    Pacheco-Barcia, Vilma
    Palka-Kotlowska, Magda
    Fernandez-Hernandez, Laura
    Del Alamo, Julio Fernandez
    Oliveros-Acebes, Eduardo
    Cabezon-Gutierrez, Luis
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (10) : 331e13 - 331e24
  • [32] Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm
    Adam B. Weiner
    Oluwarotimi S. Nettey
    Alicia K. Morgans
    Current Treatment Options in Oncology, 2019, 20
  • [33] Assessment of whether time to docetaxel impacts outcome when given in metastatic hormone-sensitive prostate cancer (MHSPC) setting
    George, S.
    Gosain, R.
    Yendamuri, K.
    Boher, J. M.
    Mescam, G. Gravis
    Sweeney, C. J.
    Hutson, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1168 - S1169
  • [34] A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive cancer
    Lam, Benjamin H. W.
    Tsang, Vivian H. M.
    Lee, M. P.
    Chan, Kuen
    Liu, Tsz Chim
    Ng, Brian Y. H.
    Wo, Barry B. W.
    Leung, K. C.
    Mui, Wing Ho
    Chan, Tim Wai
    Lam, Martin Ho Ching
    Siu, Steven W. K.
    Poon, Darren M. C.
    CLINICAL GENITOURINARY CANCER, 2024, 22 (01) : e75 - e85.e1
  • [35] Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study
    Lopez-Abad, Alicia
    Belmonte, Mario
    Backhaus, Miguel Ramirez
    Gomez, Gerardo Server
    Avellaneda, Enrique Cao
    Alarcon, Cristobal Moreno
    Cubillana, Pedro Lopez
    Gimenez, Pablo Yago
    Rodriguez, Pedro de Pablos
    Fita, Maria Jose Juan
    Duran, Miguel angel Climent
    Ruiz, Iris Guardiola
    Crespo, Natalia Vidal
    Aviles, Juan Moreno
    Martinez-Valls, Pablo Luis Guzman
    Gonzalez, Pedro angel Lopez
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (20)
  • [36] Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study
    Kafka, Mona
    Giannini, Giulia
    Artamonova, Nastasiia
    Neuwirt, Hannes
    Ofner, Heidemarie
    Kramer, Gero
    Bauernhofer, Thomas
    Luger, Ferdinand
    Hoefner, Thomas
    Loidl, Wolfgang
    Griessner, Hubert
    Lusuardi, Lukas
    Bergmaier, Antonia
    Berger, Andreas
    Winder, Thomas
    Weiss, Sarah
    Bauinger, Severin
    Krause, Steffen
    Drerup, Martin
    Heinrich, Elmar
    Schneider, Magdalena
    Madersbacher, Stephan
    Vallet, Sonia
    Stoiber, Franz
    Laimer, Sarah
    Hruby, Stephan
    Schachtner, Gert
    Nagele, Udo
    Lenart, Sebastian
    Ponholzer, Anton
    Pfuner, Jacob
    Wiesinger, Clemens
    Kamhuber, Christoph
    Muelduer, Ecan
    Bektic, Jasmin
    Horninger, Wolfgang
    Heidegger, Isabel
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 458 - 466.e1
  • [37] Triplet therapy in metastatic hormone-sensitive prostate cancer: A real-world Indian multicentre study.
    Mondal, Debapriya
    Roy, Somnath
    Bhattacharjee, Arnab
    Roy, Rakesh
    Meyur, Suman
    Biswas, Bivas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Retrospective Real-world Evaluation of Enzalutamide in Metastatic Hormone Sensitive Prostate Cancer (mHSPC) during the COVID-19 Pandemic Compared to Docetaxel in mHSPC Pre-COVID-19
    Gould, A.
    Muse, A.
    Thomson, A.
    McGrane, J.
    CLINICAL ONCOLOGY, 2023, 35 (02) : E238 - E238
  • [39] AUO First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC)
    Rexer, H.
    Feyerabend, S.
    Graefen, M.
    UROLOGIE, 2023, 62 (04): : 441 - 442
  • [40] Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy
    Yanagisawa, Takafumi
    Hata, Kenichi
    Narita, Shintaro
    Hatakeyama, Shingo
    Mori, Keiichiro
    Yata, Yuji
    Sano, Takayuki
    Otsuka, Takashi
    Hara, Shuhei
    Miyajima, Keiichiro
    Enei, Yuki
    Fukuokaya, Wataru
    Nakazono, Minoru
    Matsukawa, Akihiro
    Miki, Jun
    Habuchi, Tomonori
    Ohyama, Chikara
    Shariat, Shahrokh F.
    Kimura, Takahiro
    PROSTATE, 2023, 83 (06): : 563 - 571
12345